Related Experiment Videos
A novel glucokinase activator modulates pancreatic islet and hepatocyte function
Alexander M Efanov1, David G Barrett, Martin B Brenner
1Lilly Research Laboratories, Eli Lilly & Company, Essener Bogen 7, 22419 Hamburg, Germany. efanov_alexander@lilly.com
Endocrinology
|May 28, 2005
Summary
A novel glucokinase activator, LY2121260, enhances glucose metabolism by stimulating insulin secretion and increasing glucose uptake. This compound shows promise for managing blood glucose levels in type 2 diabetes.
Area of Science:
- Biochemistry
- Endocrinology
- Pharmacology
Background:
- Glucokinase (GK) is a critical enzyme in glucose metabolism and regulation.
- Dysregulation of GK activity is implicated in metabolic disorders like type 2 diabetes.
Purpose of the Study:
- To investigate the effects of a novel glucokinase activator, LY2121260, on enzyme activity and cellular/in vivo glucose metabolism.
- To explore the therapeutic potential of GK activators for type 2 diabetes management.
Main Methods:
- In vitro enzyme kinetics assays to determine GK activation mechanism.
- Experiments using pancreatic beta-cells and rat hepatocytes to assess insulin secretion and glucose uptake.
- In vivo studies in animal models to evaluate glucose tolerance after oral glucose challenge.
Main Results:
- LY2121260 enhanced GK activity by binding to its allosteric site.
- The activator stimulated glucose-dependent insulin secretion and increased glucose utilization in hepatocytes.
- Chronic exposure to LY2121260 led to increased GK protein levels in beta-cells.
- Animal studies demonstrated improved glucose tolerance with LY2121260 treatment.
Conclusions:
- Glucokinase activators represent a novel class of therapeutic agents.
- LY2121260 effectively modulates glucose metabolism through enhanced insulin secretion and hepatic glucose uptake.
- These findings support the potential of GK activators for controlling blood glucose in type 2 diabetes.